Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 3/2015

01-06-2015

Additive Suppression of LPS-Induced IL-10 and TNF-α by Pre-treatment of Dexamethasone and SB203580 in a Murine Alveolar Macrophage Cell Line (MH-S)

Authors: Aihong Meng, Bin Wang, Xiaopeng Zhang, Na Qi, Dengchang Liu, Jiakai Wu

Published in: Inflammation | Issue 3/2015

Login to get access

Abstract

P38 inhibitors are potent anti-inflammatory agents with distinctive mechanism of action from corticosteroid; the potential combined use of both anti-inflammatory agents could be an effective treatment for inflammatory lung disease; however, the impact of such combination on the homeostasis of immune response was poorly understood. To investigate the combined effect of dexamethasone (DEX) and/or SB203580 on tumor necrosis factor (TNF)-α (pro-inflammatory) and interleukin (IL)-10 (anti-inflammatory) secretion in mouse alveolar macrophage cell line. Secreted TNF-α and IL-10 were measured by ELISA. Phosphorylated STAT3 were investigated using Western blotting and immunocytochemistry. Pre-treatment of DEX or SB203580 inhibited lipopolysaccharide (LPS)-stimulated IL-10, TNF-α secretion, and STAT3 phosphorylation. Combined use of both agents showed stronger inhibitory effect. Combining DEX and SB203580 showed strong inhibition on the LPS-induced IL-10 secretion and STAT3 phosphorylation, which might reflect a very important drawback from the combined use of both anti-inflammatory agents.
Literature
1.
2.
Medzhitov, R., and C.A. Janeway Jr. 1997. Innate immunity: impact on the adaptive immune response. Current Opinion in Immunology 9(1): 4–9.CrossRefPubMed
3.
Simeonova, P.P., and M.I. Luster. 1995. Iron and reactive oxygen species in the asbestos-induced tumor necrosis factor-alpha response from alveolar macrophages. American Journal of Respiratory Cell and Molecular Biology 12(6): 676–83.CrossRefPubMed
4.
Zhang, Y., et al. 1993. Enhanced IL-1 beta and tumor necrosis factor-alpha release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. Journal of Immunology 150(9): 4188–96.
5.
Gosset, P., et al. 1991. Production of tumor necrosis factor-alpha and interleukin-6 by human alveolar macrophages exposed in vitro to coal mine dust. American Journal of Respiratory Cell and Molecular Biology 5(5): 431–6.CrossRefPubMed
6.
Driscoll, K.E., et al. 1990. Differential effects of mineral dusts on the in vitro activation of alveolar macrophage eicosanoid and cytokine release. Toxicology In Vitro 4(4–5): 284–8.CrossRefPubMed
7.
Dubois, C.M., E. Bissonnette, and M. Rola-Pleszczynski. 1989. Asbestos fibers and silica particles stimulate rat alveolar macrophages to release tumor necrosis factor. Autoregulatory role of leukotriene B4. American Review of Respiratory Disease 139(5): 1257–64.CrossRefPubMed
8.
Rich, E.A., et al. 1989. Dyscoordinate expression of tumor necrosis factor-alpha by human blood monocytes and alveolar macrophages. American Review of Respiratory Disease 139(4): 1010–6.CrossRefPubMed
9.
Sabat, R., et al. 2010. Biology of interleukin-10. Cytokine & Growth Factor Reviews 21(5): 331–344.CrossRef
10.
Sabat, R. 2010. IL-10 family of cytokines. Cytokine & Growth Factor Reviews 21(5): 315–324.CrossRef
11.
Filippi, C., et al. 2008. Protection against autoimmune diabetes by viral infection. FASEB Journal 22: 669–25.
12.
Villalta, S.A., et al. 2011. Interleukin-10 reduces the pathology of mdx muscular dystrophy by deactivating M1 macrophages and modulating macrophage phenotype. Human Molecular Genetics 20(4): 790–805.CrossRefPubMedCentralPubMed
13.
Stober, C.B., et al. 2005. IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection. Journal of Immunology 175(4): 2517–24.CrossRef
14.
Williams, L., et al. 2004. Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. Journal of Immunology 172(1): 567–76.CrossRef
15.
de Waal Malefyt, R., et al. 1991. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. Journal of Experimental Medicine 174(5): 1209–20.CrossRefPubMed
16.
Sharma, S., et al. 2011. IL-10 directly protects cortical neurons by activating PI-3 kinase and STAT-3 pathways. Brain Research 1373: 189–94.CrossRefPubMed
17.
Gelderblom, H., et al. 2007. Role of interleukin 10 during persistent infection with the relapsing fever Spirochete Borrelia turicatae. American Journal of Pathology 170(1): 251–62.CrossRefPubMedCentralPubMed
18.
Hualin, C., et al. 2012. The anti-inflammatory mechanism of heme oxygenase-1 induced by hemin in primary rat alveolar macrophages. Inflammation 35(3): 1087–93.CrossRefPubMed
19.
Chanteux, H., et al. 2007. LPS induces IL-10 production by human alveolar macrophages via MAPKinases- and Sp1-dependent mechanisms. Respiratory Research 8: 71.CrossRefPubMedCentralPubMed
20.
Malazdrewich, C., et al. 2004. Pharmacological inhibition of Mannheimia haemolytica lipopolysaccharide and leukotoxin-induced cytokine expression in bovine alveolar macrophages. Microbial Pathogenesis 36(3): 159–69.CrossRefPubMed
21.
Schieven, G.L. 2005. The biology of p38 kinase: a central role in inflammation. Current Topics in Medicinal Chemistry 5(10): 921–8.CrossRefPubMed
22.
Underwood, D.C., et al. 2000. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. Journal of Pharmacology and Experimental Therapeutics 293(1): 281–8.PubMed
23.
Underwood, D.C., et al. 2000. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. American Journal of Physiology - Lung Cellular and Molecular Physiology 279(5): L895–902.PubMed
24.
Wadsworth, S.A., et al. 1999. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. Journal of Pharmacology and Experimental Therapeutics 291(2): 680–7.PubMed
25.
Salituro, F.G., et al. 1999. Inhibitors of p38 MAP kinase: therapeutic intervention in cytokine-mediated diseases. Current Medicinal Chemistry 6(9): 807–23.PubMed
26.
Lee, J.C., et al. 1999. p38 mitogen-activated protein kinase inhibitors—mechanisms and therapeutic potentials. Pharmacology and Therapeutics 82(2–3): 389–97.CrossRefPubMed
27.
Lee, J.C., et al. 2000. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 47(2–3): 185–201.CrossRefPubMed
28.
Warszawska, J.M., et al. 2013. Lipocalin 2 deactivates macrophages and worsens pneumococcal pneumonia outcomes. Journal of Clinical Investigation 123(8): 3363–72.CrossRefPubMedCentralPubMed
29.
Mukherjee, S., et al. 2009. Lipopolysaccharide-driven Th2 cytokine production in macrophages is regulated by both MyD88 and TRAM. Journal of Biological Chemistry 284(43): 29391–8.CrossRefPubMedCentralPubMed
30.
Ying, H., et al. 2013. TLR4 mediates MAPK-STAT3 axis activation in bladder epithelial cells. Inflammation 36(5): 1064–74.CrossRefPubMed
31.
Hou, J., et al. 2012. Induction of interleukin-10 is dependent on p38 mitogen-activated protein kinase pathway in macrophages infected with porcine reproductive and respiratory syndrome virus. Virology Journal 9: 165.CrossRefPubMedCentralPubMed
32.
Anderson, G.P. 2008. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 372(9643): 1107–19.CrossRefPubMed
33.
Kleeberger, S.R., and D. Peden. 2005. Gene-environment interactions in asthma and other respiratory diseases. Annual Review of Medicine 56: 383–400.CrossRefPubMed
34.
Aris, R.M., et al. 1993. Ozone-induced airway inflammation in human subjects as determined by airway lavage and biopsy. American Review of Respiratory Disease 148(5): 1363–72.CrossRefPubMed
35.
Johnson, J.R., et al. 2004. Continuous exposure to house dust mite elicits chronic airway inflammation and structural remodeling. American Journal of Respiratory and Critical Care Medicine 169(3): 378–85.CrossRefPubMed
36.
37.
Mbawuike, I.N., and H.B. Herscowitz. 1989. MH-S, a murine alveolar macrophage cell line: morphological, cytochemical, and functional characteristics. Journal of Leukocyte Biology 46(2): 119–27.PubMed
38.
Matsunaga, K., et al. 2001. Alveolar macrophage cell line MH-S is valuable as an in vitro model for Legionella pneumophila infection. American Journal of Respiratory Cell and Molecular Biology 24(3): 326–31.CrossRefPubMed
Metadata
Title
Additive Suppression of LPS-Induced IL-10 and TNF-α by Pre-treatment of Dexamethasone and SB203580 in a Murine Alveolar Macrophage Cell Line (MH-S)
Authors
Aihong Meng
Bin Wang
Xiaopeng Zhang
Na Qi
Dengchang Liu
Jiakai Wu
Publication date
01-06-2015
Publisher
Springer US
Published in
Inflammation / Issue 3/2015
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-014-0093-x

Other articles of this Issue 3/2015

Inflammation 3/2015 Go to the issue

OriginalPaper

Mesenteric Lymph Duct Drainage Attenuates Acute Lung Injury in Rats with Severe Intraperitoneal Infection

OriginalPaper

Natural Killer Cell Functional Activity After 4-1BB Costimulation

OriginalPaper

Trichostatin A Protects Against Experimental Acute-on-Chronic Liver Failure in Rats Through Regulating the Acetylation of Nuclear Factor-κB

OriginalPaper

GlycA is a Novel Marker of Inflammation Among Non-Critically Ill Hospitalized Patients with Type 2 Diabetes

OriginalPaper

Simvastatin Does Not Reduce Chemokine Production in Obesity Without Comorbidities

OriginalPaper

Preventive Effects of Protocatechuic Acid on LPS-Induced Inflammatory Response in Human Gingival Fibroblasts via Activating PPAR-γ
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits